Brokerages Expect Tilray Inc (TLRY) to Post ($0.14) Earnings Per Share

Shares of Tilray Inc (NASDAQ:TLRY) have earned a consensus broker rating score of 2.00 (Buy) from the four brokers that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a hold rating and two have given a strong buy rating to the company. Tilray’s rating score has declined by 100% from 90 days ago as a result of various analysts’ ratings changes.

Brokerages have set a 1 year consensus price objective of $186.00 for the company and are expecting that the company will post ($0.14) earnings per share for the current quarter, according to Zacks. Zacks has also given Tilray an industry rank of 84 out of 257 based on the ratings given to its competitors.

TLRY has been the topic of several research analyst reports. Roth Capital initiated coverage on shares of Tilray in a research report on Tuesday, August 14th. They issued a “buy” rating and a $35.00 price objective on the stock. Benchmark initiated coverage on shares of Tilray in a research report on Tuesday, October 16th. They issued a “buy” rating and a $200.00 price objective on the stock. Zacks Investment Research upgraded shares of Tilray from a “sell” rating to a “hold” rating in a research report on Wednesday. Northland Securities cut shares of Tilray from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 6th. Finally, Cowen assumed coverage on Tilray in a research note on Monday, August 13th. They issued an “outperform” rating and a $34.00 target price for the company.

TLRY stock opened at $118.70 on Tuesday. The company has a current ratio of 0.62, a quick ratio of 0.51 and a debt-to-equity ratio of 0.24. Tilray has a 1-year low of $20.10 and a 1-year high of $300.00.

Tilray (NASDAQ:TLRY) last posted its quarterly earnings data on Tuesday, August 28th. The company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.08). The company had revenue of $9.70 million for the quarter, compared to the consensus estimate of $9.01 million. The company’s revenue was up 94.0% compared to the same quarter last year. On average, equities analysts anticipate that Tilray will post -0.48 earnings per share for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Bank of Montreal Can purchased a new stake in shares of Tilray during the third quarter valued at approximately $2,467,000. Creative Planning purchased a new stake in shares of Tilray during the third quarter valued at approximately $1,329,000. Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Tilray during the third quarter valued at approximately $1,123,000. First Mercantile Trust Co. purchased a new stake in shares of Tilray during the third quarter valued at approximately $689,000. Finally, MML Investors Services LLC purchased a new stake in shares of Tilray during the third quarter valued at approximately $438,000. 0.04% of the stock is owned by institutional investors and hedge funds.

About Tilray

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.

Featured Story: How to Invest in Growth Stocks

Get a free copy of the Zacks research report on Tilray (TLRY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply